1. JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus 
Joerg Wenzel, Nadine van Holt, Judith Maier, Maria Vonnahme, Thomas Bieber, Dominik Wolf 
Journal of Investigative Dermatology 
Volume 136, Issue 6, Pages (June 2016)
DOI: /j.jid
Copyright © 2016 The Authors Terms and Conditions

2. Figure 1
Clinical and histological findings of chilblain lupus erythematosus before and after treatment with ruxolitinib. (a–c) Erythrosquamous plaques at (a) fingers and (b) ear helix, and (c) livid nodules at the tips of the toes of a 69-year-old woman. (d) Histology of lesional biopsy of finger (hematoxylin and eosin stain). Scale bar = 100 μm; original magnification ×20. Interface dermatitis with hydropic degeneration. (e) MxA immunohistology of lesional biopsy of finger (M143-antibody with fast red as chromogen). Scale bar = 100 μm; original magnification ×10. (f, g) Clinical presentation (f) before resumption of ruxolitinib therapy and (g) after 4 months of treatment with ruxolitinib at 2 × 20 mg/d.
Journal of Investigative Dermatology  , DOI: ( /j.jid )
Copyright © 2016 The Authors Terms and Conditions